- Home
- AGEN vs BUDA Comparison
AGEN vs BUDA Comparison
Compare AGEN & BUDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGEN | BUDA |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 119.0M |
| IPO Year | 2000 | 2026 |
Fundamental Metrics
Financial Performance| Metric | AGEN | BUDA |
|---|---|---|
| Price | $3.05 | $9.45 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 613.6K | 46.8K |
| Earning Date | 03-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | ★ $106,829,000.00 | $12,486,000.00 |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $68.25 | N/A |
| P/E Ratio | ★ N/A | $25.58 |
| Revenue Growth | N/A | ★ 33.11 |
| 52 Week Low | $1.38 | $6.85 |
| 52 Week High | $7.34 | $12.00 |
Technical Indicators
Market Signals| Indicator | AGEN | BUDA |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 54.00 |
| Support Level | $2.76 | $8.65 |
| Resistance Level | $3.15 | $9.50 |
| Average True Range (ATR) | 0.18 | 0.62 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 61.00 | 48.37 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About BUDA Buda Juice Inc. Common Stock
Buda Juice Inc operates in a competitive beverage industry, focused on fresh, cold-crafted juice production for business-to-business (B2B) distribution. The Company mostly utilizes third-party delivery systems and operates within the State of Texas serving large, national chain grocery stores. It is pioneering a new category in beverages-UltraFresh juice-offering cold-crafted citrus-based drinks that are never pasteurized, never HPP- processed, never UV- treated and always cold.